Background: Aortic aneurysm (AA) is a “silent killer” human disease with no effective
treatment. Although the therapeutic potential of various pharmacological agents have been …

Background: Abdominal aortic aneurysm (AAA) is a chronic degenerative inflammatory
disease. Multi-factors including genetic, environmental and lifestyle factors determine the …

Rationale: Abdominal aortic aneurysms (AAAs) are a chronic inflammatory vascular disease
for which pharmacological treatments are not available. A mouse model of AAA formation …

580 Hypertension September 2018 below), but it was also an incentive for Lange et al2 to
test direct instead of indirect AT2R stimulation in a preclinical model of aortic aneurysm. In …

Background AT2 receptors have an unclear function on development of abdominal aortic
aneurysms (AAAs), although a pharmacological approach using the AT2 receptor antagonist …

Background—In vitro studies suggest that angiotensin II type 1 and type 2 (AT1 and AT2)
receptors exert opposite effects in terms of vasoconstriction, natriuresis, and cell growth, but …

Background Despite the importance of the renin-angiotensin (Ang) system in abdominal
aortic aneurysm (AAA) pathogenesis, strategies targeting this system to prevent clinical …

The effects of the selective AT2R (angiotensin AT2 receptor) agonist, Compound 21 (C21),
on abdominal aortic aneurysm formation were investigated in normotensive Wistar rats …

Background Our previous study developed ATRQβ-001 vaccine, which targets peptide
ATR001 from angiotensin Ⅱ (Ang Ⅱ) receptor type 1 (AT1R). The ATRQβ-001 vaccine …

Pharmacological blockade of the ANG II type 1 receptor (AT1R) is a common therapy for
treatment of congestive heart failure and hypertension. Increasing evidence suggests that …